Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/s13063-015-1101-7
Published Online: 2015-12-16
Published Print: 2015-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
Yardley, Denise A.
Brufsky, Adam
Coleman, Robert E.
Conte, Pierfranco F.
Cortes, Javier
Glück, Stefan
Nabholtz, Jean-Mark A.
O’Shaughnessy, Joyce
Beck, Robert M.
Ko, Amy
Renschler, Markus F.
Barton, Debora
Harbeck, Nadia
License valid from 2015-12-01